부산대학교 도서관

L-105, a new semisynthetic cephalosporine, was studied of the antibacterial activity, absorption and excretion, and of the clinical effects on infections in the field of internal medicine. The following are the results:1. Antibacterial activity. The activity of L-105 against clinically isolated Staphylococcus aueruswas 1 to 3 tubes stronger than that of CMZ, and 3 to 5 tubes stronger than those of CEZ, CPZ, and LMOX. Against indole-positive Proteus L-105 was similar in potency to that of CEZ and against Proteus mirabilis similar to those of LMOX and CEZ. To other drugs compared L-105 was superior in antibacterial activity.2. Absorption and excretion. L-105 and CTM were compared of their concentrations in blood and excretion in urine by single i. v. administration of 1.0g of each drug to healthy adult volunteers with cross-over method. Five min after i. v. injection, the blood concentration of L-105 and CTM was 164 μg/ml and 96 μg/ml, respectively, which decreased afterward with time, and the half-life in β-phase was 0. 833 h for L-105 and 1. 063 h for CTM. Urinary recovery rate up to 6 h after i. v. injection was 52.4% for L-105 and 58. 0% for CTM. When probenicid 1, 000mg was administered 30 min before L-105 i. v. injection, blood level tended to continue high and the rate of excretion to urine tended to be lower than when L-105 alone was administered.3. Clinical results. In one case each of pericementitis and infectious endocarditis, 2 cases of respiratory infection, 3 cases of urinary tract infection, 7 cases in total, L-105 was administered The results were 2 excellent case, 3 good cases, 1 fair case and 1 poor case. No noteworthy side effects nor abnormal laboratory test values attributable to L-105 were observed.